Infliximab
Infliximab has been studied in 2 papers since 2022: none in people yet, 1 in animals, 1 review. The research so far is in animals. The newest paper, Aug 7, 2023: “Targeting senescence and inflammation in chronic destructive TNF-driven joint pathology”.
- 1 lab in 1 country
- 6 trials, none about aging
- Animals1
What did studies of Infliximab find?
1Studies of Infliximab measured 1 outcome; the most studied are senescent chondrocytes (1 study).
Senescent chondrocytes
no changein mice1
1 study
Senescent chondrocytes
no changein mice1
Infliximab has no effect on senescent chondrocytes in mice.
“number of senescent chondrocytes (GL13+/Ki67−), assessed according to guideline algorithmic approaches, was not affected by either Dasatinib or sub-therapeutic Infliximab monotherapies”
Animalsin human TNF transgenic micejoint1 mg/kg
Targeting senescence and inflammation in chronic destructive TNF-driven joint pathology
Mechanisms of ageing and development
Trial sponsors
Company1 trialPhase 3568 people
Massachusetts General Hospital
1 trialPhase 444 people
Latest
Mechanisms of Ageing and Development
Targeting senescence and inflammation in chronic destructive TNF-driven joint pathology
Experiments in miceBones and joints